Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1983 Dec;42(3):887–889. doi: 10.1128/iai.42.3.887-889.1983

Dermal granulomatous hypersensitivity in Q fever: comparative studies of the granulomatous potential of whole cells of Coxiella burnetii phase I and subfractions.

M S Ascher, J C Williams, M A Berman
PMCID: PMC264382  PMID: 6642669

Abstract

Dermal granulomatous reactivity to Q fever antigens in guinea pigs has been described as a model for vaccine reactions seen in previously sensitized humans. This model has now been applied to study the ability of subfractions of Coxiella burnetii to produce granulomas. Q fever organisms in phase I, trichloroacetic acid-soluble and -insoluble fractions, and the extract and residue of chloroform-methanol extraction were tested for their relative ability to elicit and immunize for dermal granulomatous reactions and specific lymphocyte proliferative responses in guinea pigs. The results suggest that a determinant(s) causing granulomas can be removed by chloroform-methanol extraction of phase I whole cells. The chloroform-methanol residue elicited strong delayed-type hypersensitivity without subsequent granuloma formation. The chloroform-methanol residue appears to possess a determinant(s) for lymphocyte stimulation equivalent to that of whole phase I organisms.

Full text

PDF
887

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ANACKER R. L., HASKINS W. T., LACKMAN D. B., RIBI E., PICKENS E. G. CONVERSION OF THE PHASE I ANTIGEN OF COXIELLA BURNETII TO HAPTEN BY PHENOL TREATMENT. J Bacteriol. 1963 May;85:1165–1170. doi: 10.1128/jb.85.5.1165-1170.1963. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ascher M. S., Berman M. A., Parker D., Turk J. L. Experimental model for dermal granulomatous hypersensitivity in Q fever. Infect Immun. 1983 Jan;39(1):388–393. doi: 10.1128/iai.39.1.388-393.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ascher M. S., Berman M. A., Ruppanner R. Initial clinical and immunologic evaluation of a new phase I Q fever vaccine and skin test in humans. J Infect Dis. 1983 Aug;148(2):214–222. doi: 10.1093/infdis/148.2.214. [DOI] [PubMed] [Google Scholar]
  4. Ascher M. S., Jahrling P. B., Harrington D. G., Kishimoto R. A., McGann V. G. Mechanisms of protective immunogenicity of microbial vaccines: effects of cyclophosphamide pretreatment in Venezuelan encephalitis, Q fever and tularaemia. Clin Exp Immunol. 1980 Aug;41(2):225–236. [PMC free article] [PubMed] [Google Scholar]
  5. Crăcea E., Dumitrescu-Constantinescu S., Botez D., Ioanid L. Q-fever soluble vaccine effects in Coxiella burneti sensitized humans. Zentralbl Bakteriol Orig A. 1977 Jul;238(3):413–418. [PubMed] [Google Scholar]
  6. Fiset P., Ormsbee R. A., Silberman R., Peacock M., Spielman S. H. A microagglutination technique for detection and measurement of rickettsial antibodies. Acta Virol. 1969 Jan;13(1):60–66. [PubMed] [Google Scholar]
  7. Spicer D. S., DeSanctis A. N. Preparation of phase 1Q fever antigen suitable for vaccine use. Appl Environ Microbiol. 1976 Jul;32(1):85–88. doi: 10.1128/aem.32.1.85-88.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Williams J. C., Cantrell J. L. Biological and immunological properties of Coxiella burnetii vaccines in C57BL/10ScN endotoxin-nonresponder mice. Infect Immun. 1982 Mar;35(3):1091–1102. doi: 10.1128/iai.35.3.1091-1102.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES